KaliVir Immunotherapeutics
Stephen Thorne is a highly experienced professional currently serving as the Chief Scientific Officer at both KaliVir Immunotherapeutics and Western Oncolytics Ltd. Stephen also holds a position as a Board Member at Duo Oncology. With a background in microbiology and biochemistry, Stephen has held various research and academic roles at institutions such as the University of Pittsburgh, Stanford University, and Cancer Research UK. Thorne holds a Ph.D. in Microbiology from Imperial College London and a B.A.Sc. in Biochemistry from the University of Oxford.
KaliVir Immunotherapeutics
KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells